Study of Intravenous ZMA001 in Healthy Subjects
Conditions
- Pulmonary Arterial Hypertension PAH
Interventions
- OTHER: Placebo Cohort 1 (1.5 mg/kg/dose) only
- DRUG: ZMA001 (BC-NKA-20008)
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators